Paperonium

← Back to the plain-language case

Abstract reports 73.5% of trials used biomarkers; the Results and phase counts give 56.3%

Neurology (2026) · doi:10.1212/WNL.0000000000218373 · PMC13445500

Summary

This systematic review of 238 phase II–IV Alzheimer disease drug trials states in its abstract that "73.5% (175/238) used at least one biomarker as efficacy measures". The Results section gives 56.3% (134/238) for the same quantity. The phase-stratified counts in the Results (79/135 + 55/103 = 134/238) and the Discussion's "more than half" agree with 134, not 175. The figure 175/238 (73.5%) appears in the Results as the count of trials that used clinical outcome measures as primary measures, so the abstract seems to carry that count in the biomarker position. The abstract overstates one of the review's headline descriptive results by 41 trials (17.2 percentage points). The paper's qualitative conclusion that biomarker use is widespread still holds at 56.3%.

What the paper reports

Abstract, Results:

Among 238 included trials, 95.4% (227/238) used at least one clinical outcome and 73.5% (175/238) used at least one biomarker as efficacy measures.

Abstract, Discussion:

while biomarker use is widespread

Results, "Efficacy Measures in AD Drug Trials" (two consecutive sentences):

Among 238 included trials, 95.4% (227/238) used at least one clinical outcome measure as an efficacy measure, of which 73.5% (175/238) used clinical outcome measures as primary measures and 84.5% (201/238) as secondary measures. In addition, 56.3% (134/238) of trials used at least one biomarker as an efficacy measure, of which 11.3% (27/238) used at least one biomarker as a primary measure and 41.2% (98/238) as a secondary measure.

The next sentence in the same paragraph:

Overall, 18.1% (43/238) of trials included neither a clinical outcome measure nor a biomarker as their primary measure.

Results, "Sample Characteristics":

Of 238 included trials, 56.7% (135/238) were phase II and 43.3% (103/238) were phase III or IV.

Results, "Clinical Relevance of Efficacy Measures", phase II and phase III–IV (domains assessed overall):

functional ability and dependency (66.7%, 90/135), and biomarkers (58.5%, 79/135).

functional ability and dependency (77.7%, 80/103), and biomarkers (53.4%, 55/103).

The same paragraph, restricted to primary measures (phase II, then phase III–IV):

followed by biomarkers (14.8%, 20/135)

and biomarkers (5.8%, 6/103)

Results, same section, and Abstract, Results:

Notably, 8.4% (20/238) used biomarkers as the only primary efficacy measures.

whereas 8.4% (20/238) used biomarkers as the sole primary efficacy measure

Discussion, first paragraph and third paragraph:

Moreover, more than half of the trials evaluated biomarkers, predominantly as secondary measures

more than half of trials used biomarkers as efficacy measures

Methods, "Data Extraction" and "Data Analysis":

We also extracted whether outcome measures were evaluated as primary and secondary outcome measures or any exploratory outcome measures.

We determined the proportion of trials that used clinical outcome measures or biomarkers as any efficacy measures, primary or secondary.

What the paper's own numbers show

Method. All counts share one denominator: the 238 included trials, split into 135 phase II and 103 phase III–IV trials. I recomputed every printed percentage from its printed count. I then rebuilt the number of trials with any biomarker use from the phase-stratified counts, compared it with the abstract and the Results, and checked which other Results quantity equals 175/238. As a further check I used the primary-measure counts: the trials with a clinical or biomarker primary measure (238 − 43), the clinical-primary count (175) and the biomarker-primary count (27). Together they imply an overlap, and from it a biomarker-only primary count that can be compared with the paper's 20/238. Every number below is printed by recompute.py.txt.

Quantity Location Reported Recomputed from the paper's numbers
Trials using ≥ 1 biomarker as an efficacy measure Abstract, Results 73.5% (175/238) 175/238 = 73.53%: the arithmetic is right, but the count conflicts with the body
Trials using ≥ 1 biomarker as an efficacy measure Results, Efficacy Measures 56.3% (134/238) 134/238 = 56.30%
Abstract minus Results derived — 41 trials, 17.2 percentage points; the abstract count is 1.31 × the Results count
Trials using clinical outcomes as primary measures Results, Efficacy Measures 73.5% (175/238) 175/238 = 73.53%, the same count and percentage the abstract gives for biomarkers
Phase II, any biomarker use Results, Clinical Relevance 58.5% (79/135) 58.52%
Phase III–IV, any biomarker use Results, Clinical Relevance 53.4% (55/103) 53.40%
Sum of the phase strata derived — 135 + 103 = 238 trials; 79 + 55 = 134 biomarker trials (56.3%), equal to the Results and 41 below the abstract
Discussion: "more than half" used biomarkers Discussion — half of 238 = 119; 134 fits "more than half". 175 is close to three-quarters (178.5)
Biomarker primary + secondary Results, Efficacy Measures 27/238 (11.3%) and 98/238 (41.2%) 27 + 98 = 125, the most trials that could use a biomarker as a primary or secondary measure. 175 exceeds it by 50
Trials with a clinical or biomarker primary measure Results, Efficacy Measures 43/238 (18.1%) with neither 238 − 43 = 195
Implied trials with both clinical and biomarker primary measures derived — 175 + 27 − 195 = 7
Implied biomarker-only primary measures derived vs Results and Abstract 8.4% (20/238) 27 − 7 = 20, which matches. So 175 fits the paper's own figures as the clinical-primary count
Clinical outcome, any, primary and secondary use Results, Efficacy Measures 95.4% (227), 73.5% (175), 84.5% (201) 95.38%, 73.53%, 84.45%; 175 + 201 − 227 = 149 trials with both

Two smaller inconsistencies inside the Results came up. They do not bear on the choice between 134 and 175:

Quantity Location Reported Recomputed
Any biomarker use vs primary + secondary use Results, Efficacy Measures 134 vs 27 and 98 134 is 9 more than 27 + 98 = 125. The Methods say exploratory measures were also extracted, which could account for this, but the paper does not say so
Biomarker as primary measure, phase strata vs overall Results, Clinical Relevance vs Efficacy Measures 20/135 + 6/103 vs 27/238 20 + 6 = 26, one less than 27

Figure

The abstract's biomarker count is the Results' count of trials using clinical outcomes as primary measures

Figure 1. The two conflicting passages, quoted from the paper. Left, the abstract's Results sentence. Right, the Results paragraph "Efficacy Measures in AD Drug Trials", shortened with ellipses. Reported values are in orange. The gray connector links the abstract's biomarker figure to the identical Results figure for clinical outcomes used as primary measures. The orange connector links it to the Results figure for biomarkers, which it contradicts. The blue panel gives the value recomputed from the paper's phase-stratified counts. It matches the Results (134/238, 56.3%), not the abstract.

Counts of trials, on one axis from 0 to 238

Figure 2. The counts behind the conflict, on one axis of trials from 0 to 238. Orange circles are counts printed in the paper. Blue diamonds are counts recomputed from the paper's other figures: the sum of the phase II and phase III–IV biomarker counts (79 + 55 = 134), and the upper bound on primary or secondary biomarker use (27 + 98 = 125). The dashed line marks half of the 238 trials, the threshold of the Discussion's "more than half". The abstract's 175 equals the clinical-primary count and lies 41 trials above every other count of biomarker use in the paper.

Why it matters

The abstract's Results section opens with this figure, and for many readers the abstract is the only part of a review they read or quote. A secondary summary of the article, whose URL carries the date 25 July 2026, already repeats the abstract's figure ("73.5% of analyzed trials incorporated at least one biomarker as an efficacy endpoint").

Explanations considered

The smaller inconsistencies (134 vs 125; 26 vs 27) leave some uncertainty about the exact correct value, perhaps by a few trials. They do not bring it near 175.

Status

As of 2026-10-23:

Suggested correction

  1. In the abstract's Results, replace "73.5% (175/238) used at least one biomarker as efficacy measures" with "56.3% (134/238) used at least one biomarker as efficacy measures", if the authors' data confirm the Results figure.
  2. Reconcile the any-use count (134) with the primary and secondary counts (27 and 98, total 125). For example, state whether exploratory measures are included in "any" use. Also reconcile the phase-level biomarker-primary counts (20 + 6 = 26) with the overall 27.
  3. Check any figure or supplementary table that reports overall biomarker use (for example eTable 2) against the corrected value.